Table 2.
Comparison of clinical and pathological characteristics of carriers and non-carriers tested at Oslo University Hospital Ullevål (OUH-U)
|
BRCA 1/2 carriers (n = 13) |
Non-carriers (n = 427) |
p-values | |
|---|---|---|---|
| Below 40 years | 5 (38.5%) | 24 (5.6%) | |
| Below 50 years | 10 (76.9%) | 106 (24.8%) | |
| Below 60 years | 13 (100%) | 222 (52.0%) | |
| Age at diagnosis | |||
| Mean (95% CI) | 42 (36.1-47.9) | 57.9 (56.8-59.1) | <0.001 |
| Median (range) | 43 (26-58) | 58 (23-93) | |
| Predictive test criteria fulfilled | 4 (30.8%) | 49 (11.5%) | 0.035 |
| Stringent NBCG criteria fulfilled | 12 (92.3%) | 130 (30.4%) | <0.001 |
| TNM | (n = 13) | (n = 422) | |
| T1 | 5 (38.5%) | 261 (61.8%) | |
| T2 | 5 (38.5%) | 121 (28.7%) | 0.396 |
| T3 | 2 (15.3%) | 26 (6.2%) | |
| T4 | 1 (7.7%) | 13 (3.1%) | |
| N0 | 8 (61.5%) | 295 (72.0%) | |
| N1 | 2(15.4%) | 82 (19.4%) | 0.078 |
| N2 | 3(23.1%) | 24 (5.7%) | |
| N3 | 0 | 12 (2.8%) | |
| Distant metastasis | 0 | 2 (0.5%) | 0.76 |
| Grade | (n = 13) | (n = 419) | |
| 1 | 0 | 101 (24.1%) | 0.001 |
| 2 | 4 (30.8%) | 211 (50.4%) | |
| 3 | 9 (69.2%) | 107 (25.5%) | |
| Estrogen receptor status | (n = 13) | (n = 423) | |
| Positive | 7 (53.8%) | 371 (87.7%) | <0.001 |
| Negative | 6 (46.2%) | 52 (12.3%) | |
| Progesterone receptor status | (n = 13) | (n = 422) | 0.045 |
| Positive | 5 (38.5%) | 276 (65.4%) | |
| Negative | 8 (61.5%) | 146 (34.6%) | |
| HER2 status | (n = 13) | (n = 423) | |
| Positive | 2 (15.4%) | 57 (13.5%) | 0.84 |
| Negative | 11 (84.6%) | 366 (86.5%) | |
| Triple negative breast cancer | (n = 13) | (n = 422) | |
| 5 (38.5%) | 30 (7.1%) | <0.001 | |
| Ki67 | (n = 13) | (n = 412) | |
| Mean (95% CI) | 59 (45.3-72.8) | 31.3 (29-33) | <0.001 |
| < 30% activity | 11 (84.6%) | 182 (44.1%) | 0.004 |
NBCG Norwegian Breast Cancer Group
TNM Scoring of tumors according to the TNM Classification of Malignant Tumors
T Size of original tumor
N Involvement of regional lymph nodes
M Distant metastasis